Compile Data Set for Download or QSAR
Report error Found 131 Enz. Inhib. hit(s) with all data for entry = 12377
TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699171(US20240327430, Example 10 | US12145945, Example 10)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699172(US20240327430, Example 11 | US12145945, Example 11)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699173(US20240327430, Example 12 | US12145945, Example 12)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699174(US20240327430, Example 13 | US12145945, Example 13)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699175(US20240327430, Example 14 | US12145945, Example 14)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699176(US20240327430, Example 15 | US12145945, Example 15)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699169(US20240327430, Example 8 | US12145945, Example 8)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699170(US20240327430, Example 9 | US12145945, Example 9)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699195(2′-chloro-5′-methoxy-6-methyl-N-[6-(2-...)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699199(US20240327430, Example 39)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699200(US20240327430, Example 40 | US12145945, Example 40)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699272(2'-chloro-N-{5-[(1,1-dioxo-1-6-thietan- 3-yl)metho...)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699273(2'-chloro-N-(5-ethoxy-1,3- benzothiazol-2-yl)-5'-m...)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699274(2'-chloro-5'-methoxy-6-methyl-N-{5-[2- (trifluorom...)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699117(US20240327430, Example 1 | US12145945, Example 1)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699118(US20240327430, Example 2 | US12145945, Example 2)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699164(US20240327430, Example 3 | US12145945, Example 3)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699165(US20240327430, Example 4 | US12145945, Example 4)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699166(US20240327430, Example 5 | US12145945, Example 5)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699167(US20240327430, Example 6 | US12145945, Example 6)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699168(US20240327430, Example 7 | US12145945, Example 7)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699177(US20240327430, Example 17 | US12145945, Example 17)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699178(US20240327430, Example 19 | BDBM699185)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699179(US20240327430, Example 20 | US12145945, Example 20)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699180(US20240327430, Example 21 | US12145945, Example 21)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699181(US20240327430, Example 22 | US12145945, Example 22)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699182(US20240327430, Example 23 | US12145945, Example 23)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699183(US20240327430, Example 24 | US12145945, Example 24)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699184(US20240327430, Example 25 | US12145945, Example 25)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699178(US20240327430, Example 19 | BDBM699185)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699186(US20240327430, Example 27)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699187(US20240327430, Example 28 | US12145945, Example 28)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699188(US20240327430, Example 29 | US12145945, Example 29)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699189(US20240327430, Example 30 | US12145945, Example 30)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699190(US20240327430, Example 31 | US12145945, Example 31)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699191(US20240327430, Example 32 | US12145945, Example 32)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699192(BDBM699228 | US20240327430, Example 33)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699193(US20240327430, Example 34 | US12145945, Example 34)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699194(US20240327430, Example 35 | US12145945, Example 35)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699196(US20240327430, Example 36B | US12145945, Example 3...)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699197(US20240327430, Example 37 | US12145945, Example 37)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699198(US20240327430, Example 38 | US12145945, Example 38)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699201(US20240327430, Example 41 | US12145945, Example 41)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699202(US20240327430, Example 42 | US12145945, Example 42)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699203(US20240327430, Example 43 | US12145945, Example 43)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699204(US20240327430, Example 44 | US12145945, Example 44)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699205(US20240327430, Example 45 | US12145945, Example 45)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699206(US20240327430, Example 46 | US12145945, Example 46)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699207(US20240327430, Example 47 | US12145945, Example 47)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699208(US20240327430, Example 48 | US12145945, Example 48)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 131 total ) | Next | Last >>
Jump to: